Phase 1 N=261 A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults
Respiratory Syncytial Virus (RSV)
Primary: Percentage of Participants With Solicited Symptoms — 35.9; 73.7; 60.0; 60.0 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
Diabetes Mellitus, Type 2
Primary: Maximum Concentration (Cmax). — 90.883; 95.975; 1030.83; 986.93 ug/ml
Phase 1 N=73 Study Evaluating HKI-272 in Tumors
Breast Neoplasms
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 1 Participants
Phase 1 N=32 A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled
Healthy
Primary: AUC0-t — 38.3; 40.2; 43.6; 70.4 ng*h/mL
Phase 1 N=52 Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
Diabetes Mellitus · Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 0; 0; 0; 0 participants
Phase 1 N=9 Buspirone as a Candidate Medication for Methamphetamine Abuse
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
Phase 1 N=15 Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Maximum Tolerated Dose — 0.24 mg/kg
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 1 N=48 Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
Campylobacter Infection
Primary: Safety: Presence of Related/Not Related Local and/or Systemic Reactogenicity (Adverse Events) — 10; 17; 10; 29 Adverse Events
Phase 1 N=28 A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib
Healthy, Hepatic Insufficiency
Primary: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) — 1031; 758.9; 1189; 1378 nanogram*hour/milliliter (ng*hr/mL)
Phase 1 N=159 The Effects of Dopamine on Reward Processing
Major Depressive Disorder (MDD)
Primary: Effect on PST Reward Learning — 0.6271; 0.7575; 0.823; 0.7545 Effect size (Beta)
Phase 1 N=54 A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
Neoplasm, Advanced or Metastatic
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-117 — 4632.992; 6225.347; 6455.111; 7847.591 nanogram per milliliter (ng/mL)
Phase 1 N=36 Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adj of L-Praziquantel (L-PZQ) After Dose Adjustment — 825.2; 2066.0; 216.7…
Phase 1 N=8 Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study
Rheumatoid Arthritis
Primary: Number of Participants in Each Cluster — 0; 4; 4; 0 participants
Phase 1 N=28 Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 2; 1; 1; 1 participants